CAR T therapies drive into new terrain
Nature Reviews Drug Discovery 16, 301 (2017).
doi:10.1038/nrd.2017.84
Author: Katie Kingwell
The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: News and Analysis Source Type: research